As of 2026-03-22, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -5.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 425.05 mil USD. Aclaris's TTM EBITDA according to its financial statements is -72.11 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 10.9x | 8.7x |
| Forward P/E multiples | 12.2x - 13.7x | 12.6x |
| Fair Price | (7.14) - (6.34) | (6.19) |
| Upside | -293.5% - -271.8% | -267.7% |
| Date | EV/EBITDA |
| 2026-03-16 | -5.98 |
| 2026-03-13 | -5.64 |
| 2026-03-12 | -5.59 |
| 2026-03-11 | -5.74 |
| 2026-03-10 | -5.86 |
| 2026-03-09 | -5.39 |
| 2026-03-06 | -4.84 |
| 2026-03-05 | -4.94 |
| 2026-03-04 | -4.91 |
| 2026-03-03 | -4.81 |
| 2026-03-02 | -4.82 |
| 2026-02-27 | -4.52 |
| 2026-02-26 | -4.96 |
| 2026-02-25 | -5.26 |
| 2026-02-24 | -5.34 |
| 2026-02-23 | -5.16 |
| 2026-02-20 | -5.14 |
| 2026-02-19 | -5.13 |
| 2026-02-18 | -5.03 |
| 2026-02-17 | -5.18 |
| 2026-02-13 | -5.06 |
| 2026-02-12 | -5.34 |
| 2026-02-11 | -5.39 |
| 2026-02-10 | -5.83 |
| 2026-02-09 | -5.89 |
| 2026-02-06 | -5.69 |
| 2026-02-05 | -5.39 |
| 2026-02-04 | -5.64 |
| 2026-02-03 | -5.53 |
| 2026-02-02 | -5.76 |
| 2026-01-30 | -5.59 |
| 2026-01-29 | -5.46 |
| 2026-01-28 | -5.59 |
| 2026-01-27 | -6.20 |
| 2026-01-26 | -6.11 |
| 2026-01-23 | -7.25 |
| 2026-01-22 | -7.30 |
| 2026-01-21 | -7.12 |
| 2026-01-20 | -7.13 |
| 2026-01-16 | -4.11 |
| 2026-01-15 | -4.19 |
| 2026-01-14 | -4.31 |
| 2026-01-13 | -4.26 |
| 2026-01-12 | -4.17 |
| 2026-01-09 | -4.14 |
| 2026-01-08 | -4.21 |
| 2026-01-07 | -4.21 |
| 2026-01-06 | -4.16 |
| 2026-01-05 | -4.16 |
| 2026-01-02 | -4.54 |